EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Epidemiology and treatment of Adamantiades–Behçet's disease in Germany: A healthcare claims database study

C C Zouboulis iD, J Borchert, J Diesing, R Heinrich, W Galetzka, J-P Medelnik, A Altenburg, A Feldhus, T Schönfelder

Journal of the European Academy of Dermatology and Venereology · 2025-05 · 39 (5) · 1017-1027

DOI: 10.1111/jdv.20489 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 12.12.2024. Verfasst von C C Zouboulis und 8 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Fac…. Hauptthemen laut MEDLINE: Behcet Syndrome. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Amgen GmbH (Munich, Germany).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adamantiades–Behçet's disease (ABD) is a rare, chronic, relapsing, multisystem vasculitis, with a reported prevalence of 0.9 out of 100,000 population in Germany in 2012. However, more recent epidemiological data are lacking.

Objectives

To estimate the prevalence and incidence of ABD in Germany and assess associated comorbidities and current treatment patterns.

Methods

This retrospective cohort study used claims data from the anonymized Institute for Applied Health Research Berlin (InGef) research database. Cohorts were formed for the observation years 2016, 2017 and 2018, using data from 2013 to 2018 (allowing for a 3‐year baseline period for incidence data). The study population included patients ≥18 years old with a diagnosis of ABD (ICD‐10 diagnostic code M35.2), covered under the statutory health insurance system and in the InGef research database, with continuous insurance in the observation year and baseline period. We descriptively evaluated prevalence (≥2 outpatient ABD diagnoses in different quarters/≥1 main inpatient diagnosis in the observation year), incidence (no confirmed outpatient/inpatient diagnosis in the baseline period), comorbidities reported during the study and ABD‐related medications.

Results

We identified 300, 303 and 329 patients diagnosed with ABD in 2016, 2017 and 2018, respectively, with fewer than half (122/300 [40.7%], 127/303 [41.9%] and 150/329 [45.6%]) prescribed ≥1 disease‐related medication. In the treated population, ABD prevalence was 3.9 (2016), 4.1 (2017) and 4.7 (2018) per 100,000 population; annual ABD incidence was 0.5 per 100,000 population in 2016 and 2017 and 0.6 per 100,000 population in 2018. The most commonly reported comorbidities in patients diagnosed with ABD were dorsalgia (an indicator of possible misdiagnosis), disorders of refraction and accommodation, and essential (primary) hypertension. Prednisolone, colchicine and azathioprine were the most commonly prescribed treatments for ABD, with approximately 15% of patients taking >1 medication for ABD.

Conclusions

The reported data provide evidence that ABD remains a rare disease in Germany.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Behcet SyndromeHumansGermanyFemaleMaleAdultRetrospective StudiesIncidenceMiddle AgedDatabases, FactualPrevalenceYoung AdultComorbidityAdolescentImmunosuppressive AgentsAged

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany.
  • WIG2 GmbH Scientific Institute for Health Economics and Health System Research, Leipzig, Germany.
  • InGef - Institute for Applied Health Research Berlin GmbH, Berlin, Germany.
  • Amgen GmbH, Munich, Germany.
  • Chair Health Sciences - Public Health, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

ORCID-Profile: C C Zouboulis

Förderung

  • Amgen GmbH (Munich, Germany)

Zitieren

APA

Zouboulis, C. C., Borchert, J., Diesing, J., Heinrich, R., Galetzka, W., Medelnik, J. P., Altenburg, A., Feldhus, A., & Schönfelder, T. (2025). Epidemiology and treatment of Adamantiades–Behçet's disease in Germany: A healthcare claims database study. Journal of the European Academy of Dermatology and Venereology, 39(5), 1017-1027. https://doi.org/10.1111/jdv.20489

Vancouver

Zouboulis CC, Borchert J, Diesing J, Heinrich R, Galetzka W, Medelnik JP, et al. Epidemiology and treatment of Adamantiades–Behçet's disease in Germany: A healthcare claims database study. Journal of the European Academy of Dermatology and Venereology. 2025;39(5):1017-1027. doi:10.1111/jdv.20489

BibTeX
@article{Zouboulis2025,
  author = {Zouboulis, C C and Borchert, J and Diesing, J and Heinrich, R and Galetzka, W and Medelnik, J-P and Altenburg, A and Feldhus, A and Schönfelder, T},
  title = {Epidemiology and treatment of Adamantiades–Behçet's disease in Germany: A healthcare claims database study},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  volume = {39},
  number = {5},
  pages = {1017--1027},
  doi = {10.1111/jdv.20489}
}
Kostenlos starten →